We have a strong focus on immuno-modulatory therapeutics and the creation of fit for purpose in vitro models and assay systems to accelerate their discovery and development. We are modality agnostic. Our scientists have decades of combined expertise in the identification and characterisation of numerous drug types, ranging from small molecules and antibody-targeted therapies to the most complex of biologics.
The assay platforms, methodologies and custom solutions developed at Antibody Analytics have been applied to all of the drug classes detailed below.
Consult with our scientists and let them lead you to the right solutions for your therapeutic strategy.
mAbs of all isotypes and classes, blocking, neutralising or agonistic antibodies, Fc-enabled or silenced. Including target cell or immune cell targeted antibodies such as checkpoint inhibitors, immuno-metabolism modulators and anti-viral approaches.
Dual or multi-targeting molecules including immune cell engagers for T cells, Natural Killer (NK) cells and macrophages. Most are targeted to tumour associated antigens (TAAs) and can have traditional antibody or novel formats. Multi-functional molecules can be further engineered for stability or conjugated to recombinant cytokines to enhance local immune cell activity.
PD-1; Nivolumab, Pembrolizumab. VEGF-A; Bevacizumab, Aflibercept. F protein; Palivizumab. IL-6 Receptor; Tocilizumab. TNFα; Etanercept, Adalimumab, Infliximab, Golimumab. RANKL; Denosumab. CD20; Rituximab, Ocrelizumab. IL-12/23; Ustekinumab. Her2; Trastuzumab, Pertuzumab.
Chimeric antigen receptor T (CAR-T), T cell receptor T (TCR-T) cells, tumour infiltrating lymphocytes (TILs), engineered immune cells including macrophage, Natural Killer (NK), atypical T or innate-like cells, regulatory T cells and stem cell-derived therapies.
Antibody drug conjugates (ADCs) are frequently comprised of cytotoxic payloads targeted to cancer cells using a TAA-targeted antibody to elicit tumour cell death. Immunotherapeutic application of ADCs is growing, with the employment of immunostimulatory payloads such as chemokines, STING and toll-like receptor agonists.
Compounds designed to interfere with immune cell biology, reinvigorate immune cell function, enhance/inhibit intracellular immune cell signaling pathways or modulate immuno-metabolism. These can be used alone, or in combination with approved immunotherapies to overcome immune tolerance and suppression of effective antitumor responses.
Genetically engineered viruses can selectively target and replicate in cancer cells to induce cell death of the cancer (target) cell. Oncolytic viruses simultaneously have the potential to induce immunogenic cell death (ICD), a feature capable of inducing long-lasting anti-cancer immunity.
Innovative platform technologies have been conceived emulating many aspects of antibody-targeting function but with preferential drug characteristics such as tissue penetration, stability, manufacturability, modifiability. Novel platforms can be antibody-inspired, peptide-based or synthetic.